The No IntraCranial Haemorrhage (NOICH) Study
ISRCTN | ISRCTN29462550 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN29462550 |
Secondary identifying numbers | NTR248 |
- Submission date
- 20/12/2005
- Registration date
- 20/12/2005
- Last edited
- 13/10/2014
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr D. Oepkes
Scientific
Scientific
Leiden University Medical Centre
Department of Obstetrics
K6-31, P.O. Box 9600
Leiden
2300 RC
Netherlands
Phone | +31 (0)71 5263360 |
---|---|
D.Oepkes@lumc.nl |
Study information
Study design | Multicentre randomised single-centre active-controlled parallel-group trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Scientific title | Intravenous immunoglobulin (IvIG) in the treatment of foetal or neonatal alloimmune thrombocytopenia: a prospective, multicentre, randomised trial comparing 0.5 g and 1.0 g IvIG per kilogram bodyweight per week |
Study acronym | NOICH (No IntraCranial Haemorrhage) |
Study objectives | The hypothesis is that 0.5 g/kg/wk of IvIG is as effective as 1.0 g/kg/wk, in the prevention of intracranial haemorrhage (ICH) in foetal or neonatal alloimmune thrombocytopenia (FNAIT). |
Ethics approval(s) | Ethics approval received from the local medical ethics committee |
Health condition(s) or problem(s) studied | Foetal or neonatal alloimmune thrombocytopenia |
Intervention | Study group: low dose IvIG (0.5 g/kg/wk) control group: standard treatment: high dose IvIG (1.0 g/kg/wk) |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Applicable |
Drug / device / biological / vaccine name(s) | Intravenous immunoglobulin (IvIG) |
Primary outcome measure | Number of neonates with intracranial haemorrhage. |
Secondary outcome measures | 1. Cord blood platelet count at birth 2. Other variables studied will be the levels of maternal and neonatal anti-HPA antibodies and IgG, the occurrence of other bleedings in the neonate as well as the necessity and type of neonatal treatment |
Overall study start date | 01/01/2005 |
Completion date | 30/01/2008 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Female |
Target number of participants | 212 |
Key inclusion criteria | 1. Pregnant women with a subsequent pregnancy after prior pregnancy complicated by HPA alloimmunisation who have given birth to a child with a platelet count less than 150 x 10^9/l in the first week of life 2. HPA alloimmunisation must have been confirmed by the presence of maternal anti-HPA antibodies and the offending HPA antigen in the foetus or homozygous partner 3. The biological fathers are either homozygous positive for the HPA-type or heterozygous 4. In the case of a heterozygous father the platelet antigen genotype of the foetus will be tested before 28 weeks by amniocentesis 5. At inclusion, the pregnancy is an ultrasonographically proven intrauterine singleton pregnancy with a gestational age between 12 and 28 weeks 6. All participating patients will give written informed consent after oral and written trial information |
Key exclusion criteria | 1. Pregnant women with autoimmune thrombocytopenia 2. Twins or multiple pregnancies 3. Foetuses and neonates with major congenital anomalies or chromosomal abnormalities 4. Women who have previously given birth to children with FNAIT with ICH 5. Women who have antibodies in the first pregnancy (discovered by chance, or for instance with a sister with FNAIT) |
Date of first enrolment | 01/01/2005 |
Date of final enrolment | 30/01/2008 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
Leiden University Medical Centre
Leiden
2300 RC
Netherlands
2300 RC
Netherlands
Sponsor information
Leiden University Medical Centre (LUMC) (Netherlands)
University/education
University/education
Albinusdreef 2
P.O. Box 9600
Leiden
2300 RC
Netherlands
Website | http://www.lumc.nl/ |
---|---|
https://ror.org/027bh9e22 |
Funders
Funder type
Research organisation
Sanquin Bloodbank Amsterdam (The Netherlands)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |